Clinical Trial Update: Open-label, Follow-up of Doravirine/Islatravir (DOR/ISL 100 mg/0.75mg) for Participants With Human Immunodeficiency Virus-1 (HIV-1) Infection (MK-8591A-033) [Phase 3]

View source ↗

Summary

Open-label, Phase 3 follow-up study of the doravirine/islatravir (DOR/ISL) combination for HIV-1 infection; the trial is active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Doravirine (doravirine)
• Islatravir (Islatravir)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: HIV-1 Infection | Phase 3 | Status: ACTIVE_NOT_RECRUITING